8th Annual World Life Sciences Conference
3 Jun - 4 Jun 2022
Session information
Committee(s)
Healthcare and Life Sciences Law Committee
(Lead)
Intellectual Property and Entertainment Law Committee
(Lead)
Technology Law Committee
(Lead)
Description
Big pharma and corporate venture capital (VC) funds have begun investing in early-stage biotech/drug development companies. Often, several strategics invest in the same round. This creates an interesting dynamic with purely financial/VC investors that may invest alongside, particularly in terms of exit strategy (eg, sale v IPO, timing, possible sale to competitors). We have also seen an uptick in investment by foundations (eg, Gates Foundation), family offices and offshore investors in life science (both drug and device) companies, whether organised under US law or elsewhere, particularly from China and Korea recently. These types of investments present an array of issues, including addressing currency restrictions, local government approvals, restrictions around use of funds and rights to and protection of IP.
Session / Workshop Chair(s)
| Bill Whelan | Mintz, Boston, Massachusetts, USA |
Speakers
| Michael Margolis | Oppenheimer, New York, New York, USA |
| Brendan O’Leary | Bowen, Boston, Massachusetts, USA |